Psychedelic Stocks Surge on Trump FDA Order
April 20, 2026·17 days ago·via U.S. News & World Report
Trump orders FDA to fast-track psychedelic drug reviews, sparking a rally in makers like those pushing psilocybin for mental health. Cutting red tape frees innovation from big government strangleholds, boosting individual liberty over nanny-state bans. Critics cry risks, but evidence shows promise for veterans' PTSD without opioid traps. America First prioritizes American breakthroughs, not endless bureaucracy. This deregulatory win delivers real results. Read more about this...